LBPS
Income statement / Annual
Last year (2021), 4D pharma plc's total revenue was $718,000.00,
an increase of 34.46% from the previous year.
In 2021, 4D pharma plc's net income was -$31.94 M.
See 4D pharma plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$718,000.00 |
$534,000.00 |
$211,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$718,000.00
|
$534,000.00
|
$211,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$21.63 M
|
$22.04 M
|
$26.51 M
|
$24.91 M
|
$16.91 M
|
$10.22 M
|
$6.90 M
|
$1.82 M
|
| General & Administrative Expenses |
$15.89 M
|
$4.10 M
|
$1.57 M
|
$2.24 M
|
$2.13 M
|
$1.93 M
|
$2.24 M
|
$868,000.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$15.89 M
|
$4.10 M
|
$1.57 M
|
$2.24 M
|
$2.13 M
|
$1.93 M
|
$2.24 M
|
$868,000.00
|
| Other Expenses |
$0.00
|
$4.94 M
|
$2.74 M
|
$1.97 M
|
$1.32 M
|
$940,000.00
|
$1.46 M
|
$782,000.00
|
| Operating Expenses |
$37.52 M
|
$31.08 M
|
$30.83 M
|
$29.12 M
|
$20.36 M
|
$13.09 M
|
$10.59 M
|
$3.47 M
|
| Cost And Expenses |
$37.52 M
|
$31.08 M
|
$30.83 M
|
$29.12 M
|
$20.36 M
|
$13.09 M
|
$10.59 M
|
$3.47 M
|
| Interest Income |
$1,000.00
|
$5,000.00
|
$61,000.00
|
$282,000.00
|
$482,000.00
|
$652,000.00
|
$451,000.00
|
$92,000.00
|
| Interest Expense |
$581,000.00
|
$173,000.00
|
$514,000.00
|
$348,000.00
|
$123,000.00
|
$71,000.00
|
$0.00
|
$5,000.00
|
| Depreciation & Amortization |
$1.35 M
|
$1.21 M
|
$1.28 M
|
$1.20 M
|
$982,000.00
|
$618,000.00
|
$253,000.00
|
$114,000.00
|
| EBITDA |
-$30.03 M |
-$28.97 M |
-$27.63 M |
-$26.89 M |
-$22.88 M |
-$11.02 M |
-$9.62 M |
-$1.90 M |
| EBITDA Ratio |
-41.82
|
-54.25
|
-130.95
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-43.7
|
-56.5
|
-137.02
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$581,000.00
|
-$173,000.00
|
-$514,000.00
|
-$348,000.00
|
-$123,000.00
|
-$71,000.00
|
-$184,000.00
|
-$364,000.00
|
| Income Before Tax |
-$31.96 M
|
-$30.35 M
|
-$29.43 M
|
-$28.44 M
|
-$23.99 M
|
-$11.71 M
|
-$10.06 M
|
-$2.38 M
|
| Income Before Tax Ratio |
-44.51
|
-56.83
|
-139.46
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$22,000.00
|
-$4.38 M
|
-$5.36 M
|
-$4.75 M
|
-$3.54 M
|
-$1.84 M
|
-$2.33 M
|
$5,000.00
|
| Net Income |
-$31.94 M
|
-$25.96 M
|
-$24.07 M
|
-$23.69 M
|
-$20.45 M
|
-$9.86 M
|
-$7.73 M
|
-$2.39 M
|
| Net Income Ratio |
-44.48
|
-48.62
|
-114.06
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.3 |
-0.23 |
-0.37 |
-0.36 |
-0.31 |
-0.15 |
-0.13 |
-0.0568 |
| EPS Diluted |
-0.3 |
-0.23 |
-0.37 |
-0.36 |
-0.31 |
-0.15 |
-0.13 |
-0.0568 |
| Weighted Average Shares Out |
$107.49 M
|
$113.85 M
|
$65.49 M
|
$65.49 M
|
$65.08 M
|
$64.86 M
|
$59.82 M
|
$42.00 M
|
| Weighted Average Shares Out Diluted |
$107.49 M
|
$113.85 M
|
$65.49 M
|
$65.49 M
|
$65.08 M
|
$64.86 M
|
$59.82 M
|
$42.00 M
|
| Link |
|
|
|
|
|
|
|
|
